Partnerships & Mergers

RushData aims to address these bottlenecks by bringing antibody expression, binding analysis and early developability profiling into a standardised workflow.

Under the agreement, CORE Biomedicine will evaluate and develop the licensed programmes with the aim of creating targeted treatments for a wider range of cancer patients.

Under the proposed agreement, argenx will pay US$77 per share in cash to acquire all outstanding shares of Forte Biosciences.

Under the agreement, Sheba physicians will receive early access to new healthcare models before their wider release, while the partnership will also expand research collaboration between the two organizations.

Under the agreement, SGH-referred healthcare practitioners will have access to DataFlow’s range of services, including Premium PSV, VIP Assist, Document Concierge, licensing and credentialing support, digital footprint checks and Prometric nursing exam training.

The partnership comes as Egypt seeks to attract more patients from Arab and African markets by capitalising on its healthcare advantages.

Following the transaction, former Kira shareholders will own nearly 50% of the combined company, new private financing investors will hold slightly more than 43%, and existing Jasper shareholders will retain almost 7%.

The signing ceremony brought together National Treasury and Economic Planning Cabinet Secretary John Mbadi, U.S. Chargé d’Affaires Susan Burns, Health Cabinet Secretary Aden Duale, senior government officials and representatives from both countries.

The latest agreement aligns with Teva’s broader “Pivot to Growth” strategy, which focuses on strengthening its innovative medicines and biosimilars businesses through collaborations that expand its global pipeline.

The partnership combines GCLS’s expertise as the world’s first higher education institution dedicated exclusively to longevity science with GMU’s academic resources and Thumbay Healthcare’s extensive clinical network across the region.